CAJ | 학술논문

目的对两种α*.糖苷酶抑制剂的疗效与安全性进行评价比较。方法按1997年ADA标准诊断的2型糖尿病人60例，按1∶1分为阿卡波糖组和伏格列波糖组，经2周筛选、8周治疗并比较。结果与治疗前相比，阿卡波糖组和伏格列波糖组治疗4周和8周后，餐后1 h和2 h 血糖均有明显下降（P<0.05），但空腹血糖下降不明显(P>0.05)。阿卡波糖组在治疗8周后，餐后2h血糖下降较伏格列波糖组明显(P<0.05)。两组HbA1c治疗后较治疗前明显降低（P<0.01），组间比较差异无显著性(P>0.05)。伏格列波糖组治疗前后的空腹、餐后胰岛素水平无明显变化（P>0.05）。阿卡波糖组治疗后空腹、餐后胰岛素均明显降低(P<0.01)。两组病人治疗前后血脂无显著变化（P>0.05）。两组间治疗期间无低血糖、肝、肾功能损害发生，治疗之初常见胃肠道副作用，但可以耐受，组间比较差异无显著性。结论阿卡波糖和伏格列波糖均为有效降低餐后血糖和HbA1c的药物，阿卡波糖与伏格列波糖对控制空腹血糖及餐后血糖疗效相同，阿卡波糖降低餐后2 h血糖和胰岛素水平较伏格列波糖明显。阿卡波糖和伏格列波糖均用药安全，耐受性好。
목적대량충α*.당감매억제제적료효여안전성진행평개비교。방법안1997년ADA표준진단적2형당뇨병인60례，안1∶1분위아잡파당조화복격렬파당조，경2주사선、8주치료병비교。결과여치료전상비，아잡파당조화복격렬파당조치료4주화8주후，찬후1 h화2 h 혈당균유명현하강（P<0.05），단공복혈당하강불명현(P>0.05)。아잡파당조재치료8주후，찬후2h혈당하강교복격렬파당조명현(P<0.05)。량조HbA1c치료후교치료전명현강저（P<0.01），조간비교차이무현저성(P>0.05)。복격렬파당조치료전후적공복、찬후이도소수평무명현변화（P>0.05）。아잡파당조치료후공복、찬후이도소균명현강저(P<0.01)。량조병인치료전후혈지무현저변화（P>0.05）。량조간치료기간무저혈당、간、신공능손해발생，치료지초상견위장도부작용，단가이내수，조간비교차이무현저성。결론아잡파당화복격렬파당균위유효강저찬후혈당화HbA1c적약물，아잡파당여복격렬파당대공제공복혈당급찬후혈당료효상동，아잡파당강저찬후2 h혈당화이도소수평교복격렬파당명현。아잡파당화복격렬파당균용약안전，내수성호。
Objective　To evaluate the efficacy and safety of two kinds of Alpha-glucosidase inhibitors in treating patients with type 2 diabetes mellitus.Methods　60 type 2 diabetic patients agreed the 1997 ADA diagnosis criteria were studied. The patients were assigned to either acarbose or voglibose treatment group in 1:1 ratio. The clinical trial lasted for 10 weeks, with 2 weeks for screening and 8 weeks for treatment with either acarbose or voglibose.Results　After 4 and 8 weeks of treatment, postprandial 1-hour and 2-hour blood glucose (PBG1 and PBG2) were significantly lowered in two groups (P<0.05). But fasting blood glucose (FBG) was not significantly lowered (P>0.05). The reduction of PBG2 in acarbose group was more prominent than that in voglibose group (P<0.05). HbA1c was significantly reduced in 2 groups after 8 weeks (P<0.05). The difference in reduction of HbA1c between 2 groups was not significant. Fasting and postprandial insulin were significantly reduced in acarbose group (P<0.01). But they were not significantly reduced in voglibose group (P>0.05). As to total cholesterol, HDL-Ch, and triglycerides in two groups, no significant changes were found. Gastrointestinal side effects were frequently reported in both two groups but no significant difference was found in between two groups. Hypoglycemia, liver and renal events were not reported.Conclusion　Acarbose and voglibose significantly lower postprandial glucose and HbA1c levels. Postprandial insulin levels in acarbose group were more efficacious than that in voglibose group. They are safe and well-tolerated in general.